期刊
SCHIZOPHRENIA RESEARCH
卷 95, 期 1-3, 页码 134-142出版社
ELSEVIER
DOI: 10.1016/j.schres.2007.05.039
关键词
prepulse inhibition; schizophrenia; olanzapine; risperidone; treatment
类别
资金
- NIMH NIH HHS [R01 MH042228, R01 MH042228-18, R37 MH042228, MH-042228] Funding Source: Medline
- NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH042228, R01MH042228] Funding Source: NIH RePORTER
Prepulse inhibition (PPI), whereby the startle eyeblink response is inhibited by a relatively weak non-startling stimulus preceding the powerful startle eliciting stimulus, is a measure of sensorimotor gating and has been shown to be deficient in schizophrenia patients. There is considerable interest in whether conventional and/or atypical antipsychotic medications can normalize PPI deficits in schizophrenia patients. 51 schizophrenia patients participated in a randomized, double-blind controlled trial on the effects of three commonly-prescribed antipsychotic medications (risperidone, olanzapine, or haloperidol) on PPI, startle habituation, and startle reactivity. Patients were tested at baseline, Week 4 and Week 8. Mixed model regression analyses revealed that olanzapine significantly improved PPI from Week 4 to Week 8, and that at Week 8 patients receiving olanzapine produced significantly greater PPI than those receiving risperidone, but not haloperidol. There were no effects of medication on startle habituation or startle reactivity. These results support the conclusion that olanzapine effectively increased PPI in schizophrenia patients, but that risperidone and haloperidol had no such effects. The results are discussed in terms of animal models, neural substrates, and treatment implications. (c) 2007 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据